ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Construction Authority To Continue Under Pane’s Plan: NCAB hearing In Philadelphia

March 11, 1988

Bayh To Receive ACCC Annual Award

February 8, 1980

Senate Committee Ok’s $1.9 Billion Budget For NCI, Same As House Appropriation

July 29, 1994

BRCA Status Can Guide Ovarian Cancer Treatment

April 25, 2008

Former DCRRC Chief Saunders Proposes Total Separation Of NCI Intramural, Extramural Research

February 10, 1978

Blood Cancers Advocacy Groups Seek DOD And NCI Funds, Medicare Coverage.

July 6, 2001